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A B S T R A C T
Extracellular vesicles (EVs) released by virus-infected cells typically incorporate host and viral components
inside the vesicles (cargo molecules). Here, we investigated if human cytomegalovirus (HCMV) proteins are
incorporated in EV outer membrane released by HCMV-infected cells. We separated EVs from HCMV using an
iodixanol step-gradient and found that the separated vesicles carried EV markers such as the tetraspanin CD63
and Rab27A. Flow analysis of individual EVs demonstrated that on average, 15 ± 3.7% of EVs were positive for
gB, 5.3 ± 2.3% were positive for gH and 3.74 ± 1.5% were positive for both gB and gH. In light of previous
ﬁndings demonstrating HIV envelope proteins in EV membranes, the presence of viral protein at the surface of
EVs released by HCMV-infected cells indicated that viral membrane proteins incorporated in EVs released by
virus-infected cells may be a general phenomenon.
1. Introduction
Extracellular vesicles (EVs) are released by many, if not by all, cells
in humans. Initially identiﬁed as platelet products and thought to be
“platelet dust” (Wolf, 1967), EVs are now considered to be an important
part of cell–cell communication (Hoshino et al., 2015; Meckes, 2015;
Tkach and Thery, 2016; van Dongen et al., 2016; van Niel et al., 2018).
EVs incorporate from the cell of origin various cellular molecules such
as proteins as well as messenger RNA, small non-coding microRNAs,
and mitochondrial DNA (Bang and Thum, 2012; van Niel et al., 2018).
It has been shown that EVs generated from virus-infected cells, in
particular infected with HIV-1, may incorporate viral proteins which,
upon interaction with cells, may trigger various physiological responses
(Barclay et al., 2017; Vojtech et al., 2014). Some of these responses may
be similar to those triggered by an infectious virus (Anderson et al.,
2016). Although, the presence of viral proteins inside EVs has been
widely reported for many viruses (van Dongen et al., 2016), the pre-
sence of these proteins at the surface of EVs and their function have not
been studied extensively. We recently described the incorporation of
gp120 in EVs released by HIV-infected cells (Arakelyan et al., 2017) and
have now extended this work to a member of the herpesvirus (HHV)
family, human cytomegalovirus (HCMV). Infections with HCMV are
often associated with signiﬁcant immune activation that have in turn,
been proposed to contribute to the clinical phenotypes of disease that
are associated with HCMV infections (Deeks, 2011; Margolis, 2015).
EVs released from HHV-infected cells contain various cellular and
viral-encoded molecules (reviewed in Liu et al. (2017), Sadeghipour
and Mathias (2017)) in particular viral mRNAs and miRNAs (Canitano
et al., 2013; Han et al., 2016; Kalamvoki et al., 2014; Meckes et al.,
2010; Pegtel et al., 2010; Yogev et al., 2017) as well as viral and host
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proteins (Kalamvoki et al., 2014; Meckes et al., 2013; Miettinen et al.,
2012; Ota et al., 2014; Temme et al., 2010). Here, we report on the
presence of two HCMV envelope proteins, gB and gH that are essential
for HCMV infectivity, on the surface of EVs secreted by HCMV-infected
cells.
2. Results
We studied EVs isolated from the cell-free supernatant of UL32-
EGFP-HCMV-infected human lung ﬁbroblast (MRC-5 cells), or AD169
HCMV-infected primary dermal ﬁbroblast cells using an iodixanol step-
gradient. These EVs were concentrated in the upper fraction of the io-
dixanol gradient (between 10% and 15%). We determined the purity of
this fraction by measuring HCMV DNA by qPCR and the size and dis-
tribution using Nanosight and transmission electron microscopy (TEM).
Also, to identify contaminating HCMV virions, we stained all lipid
containing particles in a UL32-EGFP-HCMV viral preparations with a
ﬂuorescent dye, DiI. Therefore, by thresholding on DiI, any event po-
sitive for DiI and GFP represented a virion and any DiI-positive / GFP-
negative event represented a vesicle. Thus, the analysis of individual
particles allowed us to distinguish HCMV virions from EVs. Finally,
using speciﬁc ﬂuorescent antibodies, we analyzed the expression of gB
and gH, two abundant envelope glycoproteins of HCMV, on EVs.
2.1. Evaluation of HCMV in isolated fractions
To evaluate the eﬃciency of separation of the viral stocks in EV and
HCMV fractions, we measured UL32-EGFP-HCMV and AD169 HCMV
DNA by qPCR. One ml of viral preparation was separated into fractions
by iodixanol gradient centrifugation. The EV fraction, the intermediate
fraction, and the HCMV viral preparation fraction were collected
(Fig. 1A) and the genome copies of HCMV were quantiﬁed. In case of
UL32-EGFP-HCMV, 1.7 ± 0.5%, 15 ± 3.5% and 83.3 ± 3.2% of the
initial viral preparation DNA copy numbers were found respectively in
the EV, intermediate and HCMV virion fraction (Fig. 1A). A similar
distribution was found for AD169 HCMV, as 2.6 ± 0.2%, 6.6 ± 0.2%
and 90.8 ± 0.3% of the initial viral preparation DNA copy numbers
were found in the EV, intermediate and HCMV virion fraction, re-
spectively. EVs isolated from the supernatant of UL32-EGFP-HCMV-
infected cells were then characterized with NanoSight. The average
particle size of the initial HCMV preparation was 182 ± 5.3 nm, while
the size of isolated EVs (EV fraction) was on average 127 ± 1.7 nm.
The size distribution data from the nanoparticle tracking analysis of the
HCMV preparation (left panel) and EV fraction (right panel) are pre-
sented in Fig. 1B.
2.2. Detection and characterization of single particles by ﬂow virometry
We used the GFP label in UL32-EGFP-HCMV combined with ﬂow
cytometry to distinguish EVs from viral particles on an individual basis.
First, we veriﬁed that the acquired events represented single particles
rather than their aggregates. Similar to the approach reported earlier
(Arakelyan et al., 2013), we performed serial two-fold dilutions of the
DiI-labeled EVs isolated from the UL32-EGFP-HCMV viral preparation.
We acquired events using HTS on a LSRII ﬂow cytometer. We used a
gating strategy previously described in (Zicari et al., 2016) and plotted
the number of events as a function of the dilution factor. Fig. 1C (left
panel) shows a linear relation between the number of events and the
dilution factor while the mean ﬂuorescence intensity (MFI) of the
events remained constant (Fig. 1C, right panel) conﬁrming that the
visualized events represent single particles according to the earlier
published criterion (van der Pol et al., 2012).
Fig. 1. Characterization of EVs in the EV fraction. (A) HCMV DNA quantiﬁcation in iodixanol fractions. After separation on a discontinuous iodixanol gradient
using 1ml of UL32-EGFP-HCMV as input (insert), the amount of virus present in each fraction was evaluated with qPCR and presented as a percentage of the viral
input. (B) NanoSight analysis of HCMV preparation (left panel) and of isolated EV fraction (right panel). (C) Flow analysis of single EVs. DiI-stained EVs were serially
diluted two-fold from 1:2–1:1024. The events were acquired in an LSRII ﬂow cytometer, set to be triggered by DiI ﬂuorescence. Presented are the numbers of events
as a function of the dilution factor (left panel) and the median ﬂuorescence intensity (MFI) of each dilution (right panel).
S. Zicari et al. Virology 524 (2018) 97–105
98
Next, we analyzed EVs for the presence of viral proteins. EVs, de-
ﬁned as DiI-positive/GFP-negative events, constituted 99.7 ± 0.1%
(n=3) of the total events, while 0.3 ± 0.1% (n=3) were double la-
beled, thus constituting UL32-EGFP-HCMV (Fig. 2A). We assayed EVs
(DiI-positive/GFP-negative particles) released by MRC-5 cells infected
with UL32-EGFP-HCMV for the presence of HCMV envelope proteins.
Speciﬁcally, EVs isolated by iodixanol step centrifugation and labeled
with DiI were incubated with anti-gB AF647 and anti-gH PB antibodies
or with their isotype controls, IgG AF647 and IgG PB, respectively.
Labeled EVs were analyzed with ﬂow cytometry setting the threshold
on DiI ﬂuorescence. In a typical experiment presented in Fig. 2B-C,
14.7% of EVs were positive for gB and 3.9% were positive for gH. On
average, 15 ± 3.7% (n=3) of EVs were positive for gB, 5.3 ± 2.3%
(n=3) were positive for gH (Fig. 2D) and 3.74 ± 1.5% (n=3) were
positive for both gB and gH. The speciﬁcity of this staining was con-
ﬁrmed in two types of control experiments: (i) by staining with isotype
control antibodies (Fig. 2E–F) and (ii) by analysis of EVs released by
uninfected cells using the same procedure as described above
(Fig. 2G–J). Using a similar strategy and the anti-UL-85-AF647 anti-
body that speciﬁcally recognized the HCMV minor capsid protein
(UL85), we found that the HCMV capsid protein was present not only in
the HCMV fraction (DiI+/GFP+) but also in the EV fraction (DiI
+/GFP-) (Fig. 2K–N).
To conﬁrm the presence of HCMV proteins on EVs released by
HCMV-infected cells, we used our ﬂow virometry nanotechnology
(Arakelyan et al., 2013). DiI-stained EVs, collected from infected or
control uninfected MRC-5 cells and puriﬁed on iodixanol gradient, were
captured with 15-nm magnetic nanoparticles (MNPs) coupled to
speciﬁc anti-gB antibodies and labeled with Zenon AF488. As described
in the original protocol (Arakelyan et al., 2013), MNPs were used in
large excess compared with the number of virions or EVs to avoid ag-
gregation. The EV-MNP complexes were isolated on magnetic columns,
eluted, and visualized with a ﬂow cytometer. In a typical experiment,
most of the GFP-negative events (6384 events) were double-positive for
DiI and anti-gB AF488 antibodies (Fig. 3A), representing captured gB+
EVs. We detected a similar number of EVs using another method of
quantiﬁcation of the same samples: by thresholding on AF488 ﬂuores-
cence, we found that 6216 events were double-positive (Fig. 3B), re-
presenting gB+ EVs. We repeated this experiment with three diﬀerent
samples of EVs and conﬁrmed the accuracy of our quantiﬁcation:
6178.6 ± 105.4 EVs were gB+ when we thresholded on DiI and
6160 ± 30.7 EVs were gB+ when we used AF488 threshold (n=3). In
our control experiments, we applied the capture protocol on EVs iso-
lated from uninfected MRC-5 cells and found no EVs carrying gB
(Fig. 3C).
2.3. Visualization of gB-carrying EVs with electron microscopy
To conﬁrm that MNPs coupled to speciﬁc antibodies actually cap-
tured EVs, we visualized them using TEM. We analyzed EVs that were
captured with MNPs coupled to anti-gB-speciﬁc antibody. TEM re-
vealed EVs with a diameter ranging from 80 to 100 nm, of dark ap-
pearance due to the DiI and AsO4 contrasting (Belazi et al., 2009).
These EVs were attached to anti-gB-MNPs (Fig. 3D).
Fig. 2. EVs carry HCMV surface proteins. DiI-labeled EVs isolated from UL32-EGFP-HCMV were stained with anti-gB AF647 and anti-gH PB antibodies or with
their isotype controls. (A) Visualization of EVs as DiI-positive/GFP-negative events. (B) EVs stained with anti-gB AF647 antibodies or (C) with anti-gH PB antibodies.
(D) Distribution of viral antigens gB and gH on EVs isolated from UL32-EGFP-HCMV viral preparation. Presented are means (± SEM) of EVs evaluated in three
experiments. (E) Isotype control to B. (F) Isotype control to C. (G–J) DiI-labeled EVs, isolated from supernatant of control uninfected cells, were stained with anti-gB
AF647 antibodies and anti-gH PB antibodies or with their isotype controls. (G) EV fraction stained with anti-gB AF647 antibodies. (H) EV fraction stained with anti-
gH PB antibodies. (I) Isotype control to G. (J) Isotype control to H. (K-N) Detection of HCMV minor capsid protein UL-85 in EVs and HCMV by ﬂow cytometry. EV
fraction (left panel) or HCMV fraction (right panel) were stained with (upper row) or with its corresponding isotype control (lower row). (K) DiI+GVP- particles
(EVs) stained with anti UL-85-AF647 antibody (L) DiI+GFP+particles (HCMV) stained with anti UL-85-AF647 antibody. (M) Isotype control to K. (N) Isotype
control to L.
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2.4. Detection of HCMV and EV markers in HCMV and EV fractions by
western blot
Following the iodixanol gradient step puriﬁcation, both HCMV and
EV fractions obtained from AD169 HCMV viral preparation were
analyzed for HCMV and EV markers by western blot. For comparison,
we loaded similar amounts of proteins for both EV and HCMV fractions
(Fig. 4A). First, we probed HCMV and EV fractions for the presence of
the tetraspanin CD63, Rab27A, which controls diﬀerent steps of the
exosome secretion pathway, and for the presence of calnexin. Fig. 4B
Fig. 2. (continued)
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demonstrates the presence of CD63 and Rab27A in the EV fraction
while calnexin was absent. In the HCMV fraction, the expression of
CD63 and Rab27A was either absent of very weak.
Next, we probed both fractions for HCMV markers, the major capsid
protein (UL86; MCP) and the tegument protein pp150 (UL32) (Fig. 4C).
In conﬁrmation of the ﬂow cytometry ﬁndings that show the presence
of capsid protein on EVs, we found MCP in the EV fraction by western
blot. As expected both MCP and pp150 were found in the HCMV frac-
tion (Fig. 4C).
3. Discussion
Human cytomegalovirus, a member of the Herpesvirus family
(Dolan et al., 2004) encodes a large number of viral envelope proteins
(Varnum et al., 2004), including two major glycoproteins that are es-
sential for viral entry into all cell types, gB and gH, which together with
a third glycoprotein, gL, represent the fusion complex of this virus
(Vanarsdall and Johnson, 2012). Both gB and gH are important targets
of antiviral antibody responses and have been viewed as potential
components of prophylactic vaccines to limit HCMV infection and dis-
ease (Wussow et al., 2014). Moreover, HCMV gB and gH are abundant
virion envelope proteins (Varnum et al., 2004).
Recently, it became clear that viral suspensions, in particular HIV-1
and HTLV-1, are in fact complex mixtures of virions and small EVs
released by both infected and uninfected cells (Nolte-'t Hoen et al.,
2016; van Dongen et al., 2016). Here, we studied EVs released by
HCMV-infected cells.
Many EVs released by virus-infected cells are similar in size and
other physical properties to viruses such as HIV, and therefore in many
cases, it is very diﬃcult to separate these two types of particles into
pure fractions. HCMV is considerably larger than HIV, and as a result
we were able to separate EVs from virions using step-gradient cen-
trifugation. While the lower fraction (“HCMV” fraction) may contain
mature and immature virions, defective viruses, EVs that carry enough
viral components so that they acquired densities similar to that of the
virions, as well as some other unidentiﬁed particles of cellular origin,
the upper fraction contained predominantly EVs and almost no viral
DNA. Although qPCR measurements report about DNA rather than in-
tegral virions, the purity of the EV fraction was also conﬁrmed by ﬂow
analysis using a GFP+HCMV virus and therefore, we focused on par-
ticles of this upper fraction.
To conﬁrm that the particles in this fraction were actually EVs, we
probed with western blot the EV fraction for EV markers as deﬁned by
the International Society for Extracellular Vesicles (Lotvall et al., 2014).
In accordance with this deﬁnition, we demonstrated the presence of
CD63 and Rab27A and the absence of calnexin in the EV fraction. Also,
Fig. 3. EVs captured by anti-gB-magnetic
nanoparticles. DiI labeled EVs were captured
by AF488-labeled anti-gB-magnetic nano-
particles (MNPs). A typical experiment out of
three is shown. (A) DiI-labeled EVs released by
HCMV-infected cells and captured by AF488-
labeled anti-gB-MNPs; thresholding on DiI
ﬂuorescence. (B) DiI-labeled EVs released by
HCMV-infected cells captured by AF488-la-
beled anti-gB-MNPs; thresholding on AF488
ﬂuorescence. (C) DiI-labeled EVs released by
control uninfected cells and captured by
AF488-labeled anti-gB-MNPs; thresholding on
AF488 ﬂuorescence. (D) Visualization in
transmission electron microscopy of EVs from
HCMV-infected cells captured by anti-gB-
MNPs. Note the excess of MNPs that according
to the protocol (Arakelyan et al., 2013) should
be applied to capture virions and exclude their
aggregation.
Fig. 4. Detection of HCMV and EV markers in HCMV
and EV fractions by western blot. (A) stain-free blot
representing the spectrum of proteins obtained for HCMV
and EV fractions after separation of AD169 HCMV pre-
paration using a iodixanol step-gradient centrifugation.
(B) Detection of EV-associated proteins CD63 (~60 kDa),
Rab27A (~30 kDa), and calnexin (~25 kDa) proteins in
both fractions. (C) Detection of HCMV capsid protein MCP
(~150 kDa) and HCMV tegument protein, pp150
(~160 kDa) in HCMV and EV fractions after separation of
AD169 viral preparation using a iodixanol step-gradient
centrifugation.
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we found MCP in the EV fraction conﬁrming the ﬁndings from ﬂow
cytometry demonstrating the presence of the minor capsid protein,
UL85, in EVs.
As far as the HCMV fraction is concerned, as expected, we detected
both capsid (MCP) and tegument (pp150) viral proteins. We also de-
tected Rab27A but no CD63. The presence of Rab27A in the HCMV
fraction was not unexpected as Rab27A, which is recruited to the as-
sembly site, has been shown to be associated to virus-wrapping mem-
branes and incorporated into the viral envelope (Fraile-Ramos et al.,
2010). Also, the absence of CD63 on HCMV was reported earlier
(Walker et al., 2009), although other authors did ﬁnd CD63 on HCMV
(Cepeda et al., 2010; Fraile-Ramos et al., 2007). The controversy in
these data may be explained by the diﬀerence in the sensitivity of the
assays used in diﬀerent works or by diﬀerential expression of CD63 in
various cells infected by HCMV.
Although the same amount of proteins was loaded for each fraction,
it is diﬃcult to compare the amount of MCP or pp150 in HCMV with
that in EV fraction due to the diﬀerent protein composition of each
fraction as well as the diﬀerence in the size and quantities of EVs and
virions.
The above-described western blot data represent a bulk analysis that
may reﬂect the presence of small amounts of concomitant viral particles
in the EV fraction. For individual analysis of EVs, we used ﬂow cyto-
metry. First, we showed using NanoSight technology that the average
size of the initial HCMV preparation was ~ 180 nm reﬂecting the pre-
sence of virions that are approximately of 200 nm in diameter (Arvin
et al., 2007) and some smaller particles. The average size of the puriﬁed
EV fraction was ~ 130 nm.
Although the above-described data evidence that EVs were isolated
from the initial HCMV preparation, the purity of this fraction was fur-
ther accessed by ﬂow analysis which allows to focus on EVs excluding
even small contamination with HCMV virions. We stained all particles
with lipidic dye DiI and gated on GFP-negative/DiI-positive events to
exclude virions from our ﬂow analysis, and therefore focused only on
events representing EVs. However, to analyze their antigens, we ﬁrst
conﬁrmed that the acquired events represented individual particles
rather than aggregates. By demonstrating that the MFI of the events
remained constant in serially diluted samples while their concentration
was decreased according to the dilution factor, we fulﬁlled a single-
particle criterion (van der Pol et al., 2012).
Next, we investigated whether EVs released by HCMV-infected cells
carried viral membrane proteins. EVs were stained with speciﬁc ﬂuor-
escent antibodies against two HCMV glycoproteins: gB and gH. gB and
gH as noted previously are two of the most abundant HCMV envelope
glycoproteins (Varnum et al., 2004). We found that∼15% of EVs were
positive for gB and ̴∼5% were positive for gH, a proportion consistent
with the relative representation of these glycoproteins in the envelope
of the mature cell-free virus (Varnum et al., 2004). A smaller fraction
(∼4%) was positive for both viral proteins.
Thus, HCMV-infected cells release EVs that contain viral antigens
(Liu et al., 2017; Sadeghipour and Mathias, 2017). To conﬁrm this
conclusion, we investigated the antigenic composition of EVs using a
ﬂow technique originally developed in our laboratory, which allows to
analyze antigenic composition of individual EVs (Arakelyan et al.,
2013, 2017, 2015; Zicari et al., 2016). Other techniques able to analyze
individual EVs have been described as well (Morales-Kastresana et al.,
2017; van der Vlist et al., 2012).
We coupled antibodies against gB with 15-nm magnetic nano-
particles (MNPs), incubated them with DiI-labeled EVs, and then iso-
lated them in a high magnetic ﬁeld (Arakelyan et al., 2013). Flow
analysis revealed EVs released by HCMV-infected cells captured
through their gB antigen. No such EVs were present in control pre-
parations of EVs isolated from uninfected cells.
These EVs captured by anti-gB MNPs were visualized with TEM. We
found that EVs visualized by TEM were in the 50–100 nm range, which
is the characteristic of exosomes (40–150 nm) (Colombo et al., 2014;
van Dongen et al., 2016; van Niel et al., 2018). Since these captured EVs
containing HCMV gB and gH constitute a minority of the total EV po-
pulation, the imaged vesicles may constitute a speciﬁc subset of EVs, in
particular slightly smaller than the average EV as evaluated by Nano-
Sight.
Thus, similar to EVs released by HIV-infected cells, EVs released by
HCMV-infected cells also carry viral surface proteins. Such EVs may
contribute to various physiological eﬀects in which viruses have been
implicated since these EVs and HCMV should target the same cells., i.e.
cells expressing HCMV receptors. In particular, they may contribute to
the mechanisms by which exosomes secreted by HCMV-infected
HUVEC cells activate allogeneic T cells via antigen presenting cells
reported by Walker et al. (2009).
Here, we found that EVs released by HCMV-infected cells in-
corporate not only membrane HCMV proteins but also capsid proteins.
This result is in agreement with the notion that exosomes and HHVs
share biogenesis pathways (Sadeghipour and Mathias, 2017) and that in
the course of this biogenesis, EVs acquire viral proteins. As a result,
viral stock is composed of EVs, non-infectious particles and infectious
virions (Nolte-'t Hoen et al., 2016; van Dongen et al., 2016).
4. Materials and methods
4.1. Viruses, cells, and antibodies
The recombinant UL32-EGFP-HCMV virus (with GFP gene inserted
into the C terminus of the inner tegument protein pUL32 (pp150GFP-
HCMV)) was kindly provided by Drs. David Johnson (Oregon Health
Sciences University, Portland, Oregon) and Jeﬀrey Cohen (NIAID, NIH,
Bethesda, MD). It was generated as described in (Sampaio et al., 2005)
from the HCMV strain TB40 (Sinzger et al., 1999), then propagated in
human diploid ﬁbroblasts (MRC-5) in minimum essential medium
(MEM) containing 10% fetal bovine serum (FBS). Wild type AD169
CMV was produced in primary dermal ﬁbroblasts that were obtained
from discarded newborn dermal tissue. HCMV antibodies used were
monoclonal anti-gB IgG1 (Virusys Corporation, Taneytown, MD),
monoclonal anti-gH IgG1 (Thermo Fisher Scientiﬁc, Asheville, NC),
monoclonal anti-gH IgG2b (14–4b) (Bogner et al., 1992), and their
puriﬁed mouse IgG1 and IgG2b isotype control antibodies (Biolegend,
San Diego, CA).
4.2. Labeling of HCMV and EVs with DiI and separation of EVs
HCMV virions and EVs were labeled with the lipophilic tracer DiI
(Thermo Fisher Scientiﬁc): 1 ml of UL32-EGFP-HCMV viral preparation
and 1ml of AD169 HCMV were incubated with 1 µM DiI in the dark for
30min at room temperature (RT). Iodixanol (Sigma, St. Louis, MO)
discontinuous gradient was obtained by addition of four iodixanol so-
lutions prepared in phosphate buﬀered saline (PBS) (10%, 15%, 20%,
and 41%) in one 4-ml Seton open top tube (Thermo Fisher Scientiﬁc).
1 ml of DiI labeled UL32-EGFP-HCMV or WT AD169 in 5% iodixanol
were overlaid in the tube. The tube was ultracentrifuged at 130,000g
for 18 h at 4 °C with no brake. After centrifugation, the EV (between
10% and 15%), the intermediate (between 15% and 20%), and the
HCMV (between 20% and 41%) fractions were collected (Fig. 1). The
densities of the four separate iodixanol fractions (10%, 15%, 20% and
41%) used in the gradient step puriﬁcation were respectively
1.05 ± 0.005, 1.10 ± 0.007, 1.12 ± 0.008 and 1.26 ± 0.04
(n= 4). These are in the same range of densities previously reported for
similar iodixanol gradient (Walker et al., 2009).
4.3. Extraction and quantiﬁcation of HCMV DNA
200 µl aliquots of EV fraction, intermediate fraction, and HCMV
fraction were subjected to nucleic acid extraction using a NucliSENS
easyMAG 2.0 instrument (BioMérieux, Durham, NC). Quantitative real-
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time PCR (qPCR) was performed with a PerfeCTa FastMix II Low ROX
kit (Quanta BioSciences, Gaithersburg, MD) using the following primer
set: HHV-5 FWD: AACCAAGATGCAGGTGATAGG, HHV-5 REV: AGCG
TGACGTGCATAAAGA, and the probe: /56-FAM/TACCTGGAG/ZEN/
TCCTTCTGCGAGGA/3IABkFQ/. Ampliﬁcations were carried out on a
BioRad CFX96 Touch Thermocycler according to the following cycling
parameters: 2 min at 95 °C followed by 44 cycles of 10 s at 95 °C and
30 s at 60 °C.
4.4. Quantiﬁcation of EV fractions on NanoSight
EVs isolated from the cell-free supernatant of UL32-EGFP-HCMV-
infected cells and from supernatant of uninfected MRC-5 cells were
evaluated for concentration and size distribution on a NanoSight NS
300 (Salisbury, United Kingdom) equipped with a 405-nm laser and
analyzed with NTA 3.0 software (NanoSight NS300, Malvern
Instruments, UK). The measurements were performed with constant
sample ﬂow using a syringe pump for 180 s at camera level 13.
4.5. Serial dilutions of DiI-labeled EV fraction
Serial two-fold dilutions from 1:2–1:1024 of the EV fraction, iso-
lated from the UL32-EGFP-HCMV viral preparation, were performed to
show that the number of events detected with the ﬂow cytometer was
inversely linearly dependent on the dilutions analyzed. We ran samples
using a high throughput sampler (HTS) at a ﬂow rate of 1 µl/sec on a
LSRII ﬂow cytometer (BD Bioscience, San Jose, CA) that was set to
acquire 80 µl of each sample in duplicate with a threshold set at 300
ﬂuorescence units on the DiI ﬂuorescence channel.
4.6. Protein extraction, SDS-PAGE, and western blotting
Total proteins were extracted from both EV and HCMV fractions,
according to RIPA Lysis and Extraction Buﬀer (Thermo Fisher Scientiﬁc,
Waltham, MA). 10 μg of proteins were loaded on a 4–20% precast
polyacrylamide gel (Bio-Rad Laboratories, Hercules, CA) and separated
by SDS-PAGE, then transferred to PVDF membranes and probed with
anti-CD63 (1 μg/ml, Thermo Fisher Scientiﬁc, Waltham, MA), anti-
Calnexin (1 μg/ml, Thermo Fisher Scientiﬁc, Waltham, MA), anti-
Rab27A (1 μg/ml, Thermo Fisher Scientiﬁc, Waltham, MA), anti-HCMV
capsid MCP (2 μg/ml), and anti-HCMV tegument pp150 (2 μg/ml)
monoclonal primary anti-mouse monoclonal antibodies (clones 28–4
and 36–14) and then goat peroxidase-conjugated anti-mouse IgG sec-
ondary antibody (Bio-Rad Laboratories, Hercules, CA). Peroxidase ac-
tivity and digital images were detected by using V3 Western Workﬂow™
(Bio-Rad Laboratories, Hercules, CA).
4.7. Labeling of anti-gB and anti-gH detection antibodies and their isotype
controls with ﬂuorophores
Labeling of monoclonal antibodies was performed according to the
Thermo Fischer Scientiﬁc protocol. Brieﬂy, 10 µl of 1M solution of
sodium bicarbonate were added in each vial containing 100 µg of an-
tibodies (anti-gB, anti-gH, or isotype controls). Then, anti-gB and its
isotype control were labeled with Alexa Fluor 647 (AF647) while anti-
gH and its isotype control were labeled with Paciﬁc Blue (PB) in rota-
tion for 1 h at RT in the dark. During the incubation, Zeba spin desalting
columns (Thermo Fisher Scientiﬁc) were twice washed with PBS to
remove the storage buﬀer solution. After the incubation, the antibodies
were added to Zeba columns and centrifuged at 2000g for 3min, re-
covered in the ﬂow-through, and stored at 4 °C. The concentrations of
ﬂuorescent-labeled antibodies were measured with a Nanodrop 1000
(Thermo Scientiﬁc).
4.8. Detection of EV fractions with ﬂow cytometry
To stain EVs for gB and gH, an aliquot of DiI-labeled EVs (60 µl) was
incubated with 1 µg of anti-gB AF647 antibody and with 1 µg of anti-gH
PB antibody for 20min at RT. Another aliquot (60 µl) was similarly
stained with the isotype control antibodies. Also, 60 µl of DiI-labeled
EVs from uninfected MRC-5 were stained with speciﬁc antibodies or
isotype controls as an additional negative control. After 20min, the
mixture of EVs and antibodies was diluted with 240 µl of 4% paraf-
ormaldehyde (PFA). Labeled EVs were analyzed with a LSRII ﬂow
cytometer equipped with 355-, 407-, 488-, 532-, and 638-nm laser lines.
Compensation beads (BD) were used to perform compensation controls.
4.9. Intravesicular staining by ﬂow cytometry
100 µl of DiI-labeled EV fraction were incubated with 50 µl Fix and
Perm Buﬀer A (ThermoFisher Scientiﬁc) for 30min at RT, then 50 µl of
component B of Fix and Perm buﬀer were added followed by immediate
addition of either 1 µg of UL85-AF647 (in house labeled antibody
(Alexa Fluor™ 647 Antibody Labeling Kit, ThermoFisher Scientiﬁc) or
isotype control antibody in 50 µl of staining buﬀer. The mixture was
incubated for 30min at RT, ﬁxed with PBS-PFA 1% and analyzed with
ﬂow cytometer by thresholding on DiI.
4.10. Preparation of anti-gB 15-nm MNPs
1mg of 15-nm carboxyl-terminated magnetic iron oxide nano-
particles (MNPs) (OceanNanoTech, Springdale, AZ) was coupled to
IgG1 mouse monoclonal antibodies against HCMV glycoprotein gB
(Virusys Corporation, Taneytown, MD) following the Ocean Nanotech
protocol for conjugation. After the procedure, the anti-gB-coupled
MNPs were resuspended in 2ml of wash/storage buﬀer and stored at
4 °C.
4.11. Detection of EVs captured by anti-gB-MNPs with ﬂow cytometry
To visualize the fraction of EVs captured by anti-gB-MNPs, we la-
beled 60 µl of the latter with 5 µl of Zenon Alexa Fluor 488 (AF488)
mouse IgG (Thermo Fisher Scientiﬁc). Then, the ﬂuorescent anti-gB-
MNPs were incubated with 60 µl of DiI-labeled EVs from supernatant of
infected or uninfected MRC-5 cells. After 40min of incubation at 37 °C
with continuous mixing, the complexes were washed on magnetic col-
umns to remove unbound EVs, eluted in 600 µl of PBS-PFA 1%, and
analyzed using a BD LSRII ﬂow cytometer thresholding on DiI ﬂuor-
escence or on AF488 ﬂuorescence.
4.12. Preparation of EV samples captured by anti-gB-MNPs for
transmission electron microscopy
DiI-labeled EVs (240 µl) were incubated with 240 µl of anti-gB-
MNPs (~2.6×1012 MNPs/ml) for 40min at 37 °C with continuous
mixing. After the incubation, the complexes were washed three times
on MS MACS columns on an MS MACS magnet (Miltenyi Biotech,
Auburn, CA) to remove the unbound EVs and were then eluted in 240 µl
of PBS. The complexes were divided between two wells of a 24-well
plate containing 14-mm round coverslips. The plate was placed on a ﬂat
magnet for the rest of the procedure in order to keep the EV-MNPs in
the wells during all the washes. The complexes were then ﬁxed for 1 h
with 2.5% glutaraldehyde (Electron Microscopy Sciences, Hatﬁeld, PA)
in 0.1M phosphate buﬀer (PB) at pH 7.2. After 1 h, the wells were
washed three times with 0.1M PB and post-ﬁxed with 4% osmium
tetroxide (Electron Microscopy Sciences, Hatﬁeld, PA) diluted V/V in
deionized water and again V/V in 0.2M PB to obtain a solution of 1%
osmium tetroxide in 0.1 M PB. After 1 h, wells were washed three times
with 0.1M PB, and then the samples were dehydrated sequentially with
two 10-min incubations in 70% ethanol, two 10-min incubations in
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90% ethanol, and two 10-min incubations in 100% ethanol. We per-
formed the embedding steps using the EMbed Resin previously pre-
pared with the EMbed-812 kit (Electron Microscopy Sciences, Hatﬁeld,
PA). The ﬁrst 10-min incubation was done with EMbed Resin diluted V/
V in 100% ethanol. The second 10-min incubation was done with pure
EMbed Resin. After this step, two Beem Embedding Capsules per well
were ﬁlled with pure EMbed Resin and then ﬂipped vertically over the
beads in the wells. The polymerization step was done at 60 °C for 24 h,
avoiding humidity. Capsules were detached mechanically from the
plastic and 80-nm sections were then cut with an ultramicrotome
(Reichert Ultracut S) as described in Ganor et al. (Ganor et al., 2010)
and observed with a transmission electron microscope (JEOL 1011)
equipped with a GATAL numerical camera. Pictures were taken and
digitalized with Digital Micrograph software at the Electron Microscopy
Facility of the Cochin Institute. At least 50 randomly chosen ﬁelds were
observed per duplicate.
4.13. Statistical analysis
The results are presented as means± standard errors of the mean
(SEM), and n, the number of replicates, is indicated.
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